By removing N-glycans from PD-L1, the Hung group discovered that deglycosylation significantly improves anti-PD-L1 antibody binding affinity, thus resulting in a more accurate PD-L1 quantification and prediction of clinical outcome in breast cancer (88). Here, CD274 is linked to breast cancer.